Ocular Toxicity Profile of ST-162 and ST-168 as Novel Bifunctional MEK/PI3K Inhibitors
- J Ocul Pharmacol Ther. 2018 Jul/Aug;34(6):477-485. doi: 10.1089/jop.2017.0126.
- 1. 1 Department of Ophthalmology and Visual Sciences, University of Michigan , Medical School, Ann Arbor, Michigan.
- 2. 2 Department of Radiology and Biological Chemistry, Center for Molecular Imaging, University of Michigan , Medical School, Ann Arbor, Michigan.
- 3. 3 Department of Radiology, University of Michigan , Medical School, Ann Arbor, Michigan.
- 4. 4 Department of Chemical Engineering, University of Michigan , Medical School, Ann Arbor, Michigan.
- 5. 5 Department of Biological Chemistry, University of Michigan , Medical School, Ann Arbor, Michigan.
Purpose: ST-162 and ST-168 are small-molecule bifunctional inhibitors of MEK and PI3K signaling pathways that are being developed as novel antitumor agents. Previous small-molecule and biologic MEK inhibitors demonstrated ocular toxicity events that were dose limiting in clinical studies. We evaluated in vitro and in vivo ocular toxicity profiles of ST-162 and ST-168.
Methods: Photoreceptor cell line 661W and adult retinal pigment epithelium cell line ARPE-19 were treated with increasing concentrations of bifunctional inhibitors. Western blots, cell viability, and Caspase activity assays were performed to evaluate MEK and PI3K inhibition and dose-dependent in vitro toxicity, and compared with monotherapy. In vivo toxicity profile was assessed by intravitreal injection of ST-162 and ST-168 in Dutch-Belted rabbits, followed by ocular examination and histological analysis of enucleated eyes.
Results: Retinal cell lines treated with ST-162 or ST-168 exhibited dose-dependent inhibition of MEK and PI3K signaling. Compared with inhibition by monotherapies and their combinations, bifunctional inhibitors demonstrated reduced cell death and Caspase activity. In vivo, both bifunctional inhibitors exhibited a more favorable toxicity profile when compared with MEK Inhibitor PD0325901.
Conclusions: Novel MEK and PI3K bifunctional inhibitors ST-162 and ST-168 demonstrate favorable in vitro and in vivo ocular toxicity profiles, supporting their further development as potential therapeutic agents targeting multiple aggressive tumors.